Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
| dc.contributor.advisor | ||
| dc.contributor.author | Jara, Alejandro | |
| dc.contributor.author | Undurraga, Eduardo | |
| dc.contributor.author | González, Cecilia | |
| dc.contributor.author | Paredes, Fabio | |
| dc.contributor.author | Fontecilla, Tomás | |
| dc.contributor.author | Jara, Gonzalo | |
| dc.contributor.author | Pizarro, Alejandra | |
| dc.contributor.author | Acevedo, Johanna | |
| dc.contributor.author | Leo, Katherinne | |
| dc.contributor.author | Leon, Francisco | |
| dc.contributor.author | Sans, Carlos | |
| dc.contributor.author | Leighton, Paulina | |
| dc.contributor.author | Suárez, Pamela | |
| dc.contributor.author | García-Escorza, Heriberto | |
| dc.contributor.author | Araos, Rafael | |
| dc.date.accessioned | 2022-05-06T20:55:28Z | |
| dc.date.available | 2022-05-06T20:55:28Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | BACKGROUND Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making. A countrywide mass vaccination campaign with the use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021. METHODS We used a prospective national cohort, including participants 16 years of age or older who were affiliated with the public national health care system, to assess the effectiveness of the inactivated SARS-CoV-2 vaccine with regard to preventing Covid-19 and related hospitalization, admission to the intensive care unit (ICU), and death. We estimated hazard ratios using the extension of the Cox proportional-hazards model, accounting for time-varying vaccination status. We estimated the change in the hazard ratio associated with partial immunization (≥14 days after receipt of the first dose and before receipt of the second dose) and full immunization (≥14 days after receipt of the second dose). Vaccine effectiveness was estimated with adjustment for individual demographic and clinical characteristics. RESULTS The study was conducted from February 2 through May 1, 2021, and the cohort included approximately 10.2 million persons. Among persons who were fully immunized, the adjusted vaccine effectiveness was 65.9% (95% confidence interval [CI], 65.2 to 66.6) for the prevention of Covid-19 and 87.5% (95% CI, 86.7 to 88.2) for the prevention of hospitalization, 90.3% (95% CI, 89.1 to 91.4) for the prevention of ICU admission, and 86.3% (95% CI, 84.5 to 87.9) for the prevention of Covid-19–related death. | es |
| dc.description.version | Versión Publicada | es |
| dc.identifier.citation | Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, Sans C, Leighton P, Suárez P, García-Escorza H, Araos R. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021 Sep 2;385(10):875-884. doi: 10.1056/NEJMoa2107715. Epub 2021 Jul 7. PMID: 34233097; PMCID: PMC8279092. Copy | es |
| dc.identifier.uri | https://doi.org/10.1056/NEJMoa2107715 | es |
| dc.identifier.uri | http://hdl.handle.net/11447/6066 | |
| dc.language.iso | en | es |
| dc.subject | Sars-CoV-2 | es |
| dc.subject | Vaccine | es |
| dc.title | Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile | es |
| dc.type | Article | es |
| dcterms.source | The New England Journal of Medicine | es |